Comparative Pharmacology
Head-to-head clinical analysis: PLAQUENIL versus QUININE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLAQUENIL versus QUININE SULFATE.
PLAQUENIL vs QUININE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.
Quinine sulfate is a blood schizonticide effective against the asexual erythrocytic forms of Plasmodium spp. It interferes with the parasite's ability to digest hemoglobin, leading to accumulation of toxic heme and parasite death. Quinine also has mild analgesic and antipyretic effects, and may depress cardiac conduction and contractility.
400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day
324 mg orally every 8 hours for 7 days (for treatment of chloroquine-resistant falciparum malaria, in combination with other antimalarials).
None Documented
None Documented
Terminal elimination half-life: 32-50 days (range 22-124 days) due to extensive tissue distribution and slow release from melanin-rich tissues; requires long-term dosing to achieve steady state (3-6 months).
Terminal elimination half-life: 18 hours (range 16-21 hours) in healthy adults; prolonged in renal impairment (up to 25-30 hours) and severe hepatic impairment.
Renal (50-70% unchanged), fecal (20-30% as metabolites), minor biliary.
Renal: 20% unchanged; hepatic metabolism (CYP3A4, CYP2C9) accounts for 80% with metabolites (primarily 3-hydroxyquinine) excreted renally and fecally. Biliary excretion is minor (<5%).
Category C
Category D/X
Antimalarial
Antimalarial